Analisis Efektivitas Regimen Terapi Antiretroviral terhadap Status Viral Load pada Pasien HIV di Puskesmas Umbulharjo 1 dan Gedongtengen
Effectiveness Analysis of Antiretroviral Therapy Regimens on Viral Load Status Among HIV Patients at Umbulharjo 1 and Gedongtengen Community Health Centers
DOI:
https://doi.org/10.35473/ijpnp.v8i01.4001Keywords:
HIV, TLD, TLE, Viral LoadAbstract
Human Immunodeficiency Virus (HIV) remains a major public health challenge, including in the Special Region of Yogyakarta. This study compares the effectiveness of two first-line antiretroviral therapy (ART) regimens, namely TLD (Tenofovir-Lamivudine-Dolutegravir) and TLE (Tenofovir-Lamivudine-Efavirenz), in reducing viral load among HIV patients at two community health centers. A retrospective cohort design using convenience sampling was conducted based on medical records from Gedongtengen Community Health Center (January 2021–June 2023) and Umbulharjo 1 Community Health Center (January 2021–December 2022). Inclusion criteria comprised adult patients (≥17 years) who received TLD or TLE for at least six months and had complete viral load data. Statistical analyses (chi-square test, odds ratio) were performed on 102 patients (mean age 28.94 ± 9.98 years; 90.2% male). The majority (96.1%) were in early stages (1–2) of HIV infection, and 6.9% had opportunistic infections. Viral load suppression was achieved in 52% of patients receiving TLD compared to 21% in the TLE group (p = 0.015; OR = 3.01). The superior efficacy of TLD is attributed to Dolutegravir’s mechanism as an integrase inhibitor with a high barrier to resistance. Despite some limitations, these findings support prioritizing TLD as the preferred first-line ART regimen, particularly for patients in early stages of HIV infection.
ABSTRAK
Human Immunodeficiency Virus (HIV) menjadi tantangan utama kesehatan masyarakat, termasuk di Daerah Istimewa Yogyakarta. Penelitian ini membandingkan efektivitas dua regimen terapi antiretroviral (ART) lini pertama, yaitu TLD (Tenofovir-Lamivudine-Dolutegravir) dan TLE (Tenofovir-Lamivudine-Efavirenz) dalam menurunkan viral load pasien HIV di dua puskesmas. Metode yang digunakan yaitu kohort retrospektif dengan convenience sampling dilakukan pada rekam medis di Puskesmas Gedongtengen (Januari 2021–Juni 2023) dan Puskesmas Umbulharjo 1 (Januari 2021–Desember 2022). Kriteria inklusi meliputi pasien dewasa (≥17 tahun) yang menerima TLD/TLE minimal selama 6 bulan dan memiliki data viral load lengkap. Analisis statistik (chi-square, odds ratio) dilakukan pada 102 pasien (rerata usia 28,94 ± 9,98 tahun; 90,2% laki-laki). Sebanyak 96,1% berada pada stadium awal (1–2) dan 6,9% mengalami infeksi oportunistik. Penekanan viral load tercapai pada 52% pasien penerima TLD, dibandingkan 21% pada TLE (p = 0,015; OR = 3,01). Keunggulan TLD diduga disebabkan oleh mekanisme Dolutegravir sebagai penghambat integrase dengan high resistance barrier. Meskipun memiliki keterbatasan, temuan ini mendukung prioritas TLD sebagai regimen ART lini pertama, khususnya bagi pasien stadium awal HIV.
References
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., Hagins, D., Felizarta, F., Madruga, J., Reuter, T., Newman, T., Small, C. B., Lombaard, J., Grinsztejn, B., Dorey, D., … extended SAILING Study Team. (2013). Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet (London, England), 382(9893), 700–708. https://doi.org/10.1016/S0140-6736(13)61221-0
Clavel, F., & Hance, A. J. (2004). HIV drug resistance. The New England Journal of Medicine, 350(10), 1023–1035. https://doi.org/10.1056/NEJMra025195
WHO. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. World Health Organization. https://www.who.int/publications/i/item/9789240031593
Dinas Kesehatan Kota Yogyakarta. (2023). Profil Kesehatan Kota Yogyakarta Tahun 2023. https://kesehatan.jogjakota.go.id/berita/id/470/profil-kesehatan-kota-yogyakarta-tahun-2023/
Faisal, N., Azis, R., & Syafar, M. (2021). Analisis Faktor yang Mempengaruhi Tindakan Pencegahan Penularan HIV oleh ODHA Pada Orang lain. Jurnal Ilmiah Kesehatan Sandi Husada, 10(2), 332–339. https://doi.org/10.35816/jiskh.v10i2.615
Kementerian Kesehatan. (2022). Peraturan Menteri Kesehatan Nomor 23 Tahun 2022 tentang Penanggulangan Human Immunodeficiency Virus, Acquired Immuno-Deficiency Syndrome, dan Inkubasi Menular Seksual.
Kementerian Kesehatan Republik Indonesia. (2017). Pedoman nasional tatalaksana HIV dan terapi antiretroviral.
Kementerian Kesehatan Republik Indonesia. (2021). Surat Edaran Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Nomor PM.02.04/III/2919/2021 tentang Rekomendasi Terapi Antiretroviral Lini Pertama HIV/AIDS dan IMS.
Kementerian Kesehatan RI. (2022). Laporan eksekutif perkembangan HIV AIDS dan penyakit infeksi menular seksual (PIMS) triwulan IV tahun 2022.
Mahale, P. R., Patel, B. S., & Kasmani, N. (2023). Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV. Cureus. https://doi.org/10.7759/cureus.40139
Meireles, M. V., Pascom, A. R. P., Duarte, E. C., & McFarland, W. (2019). Comparative effectiveness of first-line antiretroviral therapy. AIDS, 33(10), 1663–1668. https://doi.org/10.1097/QAD.0000000000002254
Ngletih, P. (2020). Kelompok yang beresiko tertular HIV / AIDS. Dinas Kesehatan Kota Kediri. https://dinkes.kedirikota.go.id/p/edukasi-e-lahab-kelompok- yang-beresiko-tertular-hiv-aids
Puspitasari, W. D., Yasin, N. M., & Rahmawati, F. (2018). Comparison of Treatment Outcomes among Second-Line Antiretroviral Regimens in HIV/AIDS Patient. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice), 8(3), 119. https://doi.org/10.22146/jmpf.36414
Saag, M. S., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Thompson, M. A., Sax, P. E., Smith, D. M., Benson, C. A., Buchbinder, S. P., Del Rio, C., Eron, J. J., Fätkenheuer, G., Günthard, H. F., Molina, J.-M., Jacobsen, D. M., & Volberding, P. A. (2020). Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA, 324(16), 1651–1669. https://doi.org/10.1001/jama.2020.17025
UNAIDS. (2024). Understanding measures of progress towards the 95–95–95 HIV testing, treatment and viral suppression targets. Joint United Nations Programme on HIV/AIDS.
WHO. (2021a). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. World Health Organization.
WHO. (2021b). Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: Accountability for the global health sector strategies 2016–2021: actions for impact. WHO.
WHO. (2023). The role of HIV viral suppression in improving individual health and reducing transmission: Policy brief.
WHO. (2024). HIV statistics, globally and by WHO region. Https://Www.Who.Int/Teams/Global-Hiv-Hepatitis-and-Stis-Programmes/Hiv/Strategic-Information/Hiv-Data-and-Statistics.
